Amarin Corporation

Executive Summary

Amarin Corporation is a commercial-stage biopharmaceutical company focused on cardiovascular health, with its sole marketed product VASCEPA (icosapent ethyl) approved for reducing cardiovascular risk in certain patients. The company generated approximately $600 million in revenue in 2025, driven by strong prescription trends and expanded insurance coverage. However, Amarin faces patent challenges and generic competition in the US, with VASCEPA's key patents expiring in 2029. The company is pursuing international expansion, including regulatory approvals in China and other markets, to diversify revenue. Its pipeline is limited, with early-stage candidates for cardiovascular and inflammatory indications. Financially, Amarin has a solid balance sheet with no debt and sufficient cash to fund operations, but profitability remains elusive. The stock trades at a discount to peers due to concerns about long-term growth prospects and the lack of a robust pipeline.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on label expansion for VASCEPA in additional patient populations40% success
• Q2 2027China regulatory approval for VASCEPA70% success
• Q3 2027Phase 2 data readout for new pipeline candidate in cardiovascular disease30% success